## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.3% below STRENGTH zone (3.0-6.0%); PEG 3.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. HSBC Adjusts Price Target on GE Healthcare Technologies to $100 From $87, Maintains Buy Rating**
- Source: marketscreener.com | 20251208T130814 | Bullish | Relevance: 98%
-  HSBC has raised its price target for GE Healthcare Technologies (GEHC) from $87 to $100, while reiterating a "Buy" rating on the stock. This adjustment comes amidst ongoing news about GE HealthCare's strategic developments, including new partnerships and technological advancements in medical imaging and diagnostics. The company continues to declare quarterly dividends and introduces advanced solutions powered by AI and NVIDIA technology.

**2. Barclays Reaffirms Their Hold Rating on GE Healthcare Technologies Inc (GEHC)**
- Source: The Globe and Mail | 20251207T140814 | Neutral | Relevance: 98%
-  Barclays analyst Matt Miksic has maintained a Hold rating on GE Healthcare Technologies Inc (GEHC) with a price target of $86.00. This follows similar Hold ratings from other firms, though Goldman Sachs recently issued a Buy rating. GE Healthcare Technologies reported quarterly revenue of $5.14 billion and a net profit of $446 million for the quarter ending September 30.

**3. 18,934 Shares in GE HealthCare Technologies Inc. $GEHC Bought by London & Capital Asset Management Ltd**
- Source: MarketBeat | 20251209T131728 | Bullish | Relevance: 98%
-  London & Capital Asset Management Ltd recently acquired 18,934 shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the second quarter, valued at approximately $1.4 million. Several other institutional investors have also adjusted their holdings in GEHC, indicating significant institutional interest. The company recently reported its quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**4. Barclays Reaffirms Their Hold Rating on GE Healthcare Technologies Inc (GEHC)**
- Source: The Globe and Mail | 20251206T220931 | Bullish | Relevance: 98%
- Barclays has reaffirmed its Hold rating on GE Healthcare Technologies Inc (GEHC) with a price target of $86.00, according to analyst Matt Miksic. This recommendation aligns with another Hold rating from Bank of America Securities, while Goldman Sachs maintains a Buy rating on the stock. GE Healthcare Technologies reported quarterly revenue of $5.14 billion and a net profit of $446 million for the quarter ending September 30.

**5. Guggenheim Capital LLC Purchases 24,087 Shares of GE HealthCare Technologies Inc. $GEHC**
- Source: MarketBeat | 20251206T113353 | Somewhat-Bullish | Relevance: 97%
- Guggenheim Capital LLC increased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 22.3% during the second quarter, buying an additional 24,087 shares and bringing its total holdings to 131,985 shares valued at $9.776 million. Other institutional investors also adjusted their positions in GE HealthCare Technologies, which recently announced a quarterly dividend and reported earnings slightly above consensus estimates. The company's stock shows a 50-day moving average of $75.95 and a 200-day moving average of $74.47, with several analysts maintaining "Buy" or "Hold" ratings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.9B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 16.8 |
| Current P/E | 18.3 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 1.3% (minimal 5-day change). Below STRENGTH zone by 1.7pp (needs >3.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.84), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.26% (CS: 68) | Neutral |
| RSI_14 | 63.0 | Neutral |
| MACD Histogram | 0.84 | Bullish |
| vs SMA20 | 1.074x | Above |
| vs SMA50 | 1.093x | Above |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.09
- **Stop Loss:** $78.39 (5.7% risk)
- **Target:** $87.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $8,807.54
- **Portfolio %:** 8.81%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*